Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

Lilly's experimental amylin drug, when combined with Zepbound, showed promising results in helping people shed up to 23% of their body weight, a significant achievement in the battle against obesity and diabetes. However, the trial also highlighted a notable increase in side effects compared to Zepbound alone. This development underscores the ongoing challenge of balancing efficacy with safety in weight-loss medications, and it could potentially lead to new, more effective treatments if the side effects can be managed or mitigated.